Hepatic glucose output

Hepatic glucose output refers to the process by which the liver releases glucose into the bloodstream, primarily through gluconeogenesis (generating glucose from non-carbohydrate sources) and glycogenolysis (breakdown of glycogen stores)[1][4][5][7]. In the fasted state, this process is essential for maintaining normal blood glucose levels and supplying energy to tissues, especially the brain and red blood cells. Hepatic glucose output is tightly regulated by hormones such as insulin (which suppresses output) and glucagon (which stimulates output)[1][2][3][7][9]. Dysregulation or excessive hepatic glucose output is a central pathophysiological feature of type 2 diabetes mellitus, leading to fasting and postprandial hyperglycemia[1][2][4]. Numerous drugs used in diabetes therapy exert part of their benefit by inhibiting hepatic glucose output, notably metformin (which acts primarily by inhibiting gluconeogenesis) and insulin (which promotes hepatic glucose uptake and inhibits output)[1][7][9]. Monitoring hepatic glucose output (usually indirectly, via plasma glucose or tracer studies) is crucial in diabetes research and management. As a process and not a discrete molecule, hepatic glucose output should not be listed as a canonical molecular drug target, but rather as a key physiological endpoint influenced by intervention at multiple molecular sites.

Other names

Hepatic glucose productionHepatic glucose releaseEndogenous glucose productionHGP

Inhibition of gluconeogenic enzymes (e.g., metformin inhibits mitochondrial glycerol-3-phosphate dehydrogenase, reducing gluconeogenesis from glycerol)[1]\nInsulin-mediated repression of gluconeogenic gene expression and stimulation of glycogen synthesis[1][7][9]\nGlucagon-mediated activation of gluconeogenesis and glycogenolysis via cAMP-dependent signaling[2][3][7]